Aghajanian C - Search Results

1

TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Aghajanian C, Samuelson MI, Lankes HA, Soslow RA, Leslie KK. Thiel KW, et al. Among authors: aghajanian c. J Clin Oncol. 2022 Oct 1;40(28):3289-3300. doi: 10.1200/JCO.21.02506. Epub 2022 Jun 3. J Clin Oncol. 2022. PMID: 35658479 Free PMC article. Clinical Trial.

2

Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.

Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A, Venkatraman E, Aghajanian C, Hensley M, Soignet S, Brown C, Soslow R, Markman M, Hoskins WJ, Spriggs D. Barakat RR, et al. Among authors: aghajanian c. J Clin Oncol. 2002 Feb 1;20(3):694-8. doi: 10.1200/JCO.2002.20.3.694. J Clin Oncol. 2002. PMID: 11821450

3

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, Venkatraman E, Spriggs DR. Dizon DS, et al. Among authors: aghajanian c. J Clin Oncol. 2002 Mar 1;20(5):1238-47. doi: 10.1200/JCO.2002.20.5.1238. J Clin Oncol. 2002. PMID: 11870166

4

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Hensley ML, et al. Among authors: aghajanian c. J Clin Oncol. 2002 Jun 15;20(12):2824-31. doi: 10.1200/JCO.2002.11.050. J Clin Oncol. 2002. PMID: 12065559 Clinical Trial.

5

Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.

Sabbatini P, Aghajanian C, Leitao M, Venkatraman E, Anderson S, Dupont J, Dizon D, O'Flaherty C, Bloss J, Chi D, Spriggs D. Sabbatini P, et al. Among authors: aghajanian c. Clin Cancer Res. 2004 May 1;10(9):2962-7. doi: 10.1158/1078-0432.ccr-03-0486. Clin Cancer Res. 2004. PMID: 15131031 Clinical Trial.

6

Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.

Leitao MM, Soslow RA, Nonaka D, Olshen AB, Aghajanian C, Sabbatini P, Dupont J, Hensley M, Sonoda Y, Barakat RR, Anderson S. Leitao MM, et al. Among authors: aghajanian c. Cancer. 2004 Sep 15;101(6):1455-62. doi: 10.1002/cncr.20521. Cancer. 2004. PMID: 15316901 Free article.

7

Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Sabbatini P, Aghajanian C, Dizon D, Anderson S, Dupont J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D. Sabbatini P, et al. Among authors: aghajanian c. J Clin Oncol. 2004 Nov 15;22(22):4523-31. doi: 10.1200/JCO.2004.12.043. J Clin Oncol. 2004. PMID: 15542803 Clinical Trial.

8

Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.

Hensley ML, Correa DD, Thaler H, Wilton A, Venkatraman E, Sabbatini P, Chi DS, Dupont J, Spriggs D, Aghajanian C. Hensley ML, et al. Among authors: aghajanian c. Gynecol Oncol. 2006 Aug;102(2):270-7. doi: 10.1016/j.ygyno.2005.12.042. Epub 2006 Feb 20. Gynecol Oncol. 2006. PMID: 16490239 Clinical Trial.

9

Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study.

Sovak MA, Hensley ML, Dupont J, Ishill N, Alektiar KM, Abu-Rustum N, Barakat R, Chi DS, Sabbatini P, Spriggs DR, Aghajanian C. Sovak MA, et al. Among authors: aghajanian c. Gynecol Oncol. 2006 Nov;103(2):451-7. doi: 10.1016/j.ygyno.2006.03.019. Epub 2006 May 3. Gynecol Oncol. 2006. PMID: 16677690

10

Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival.

Diefenbach CS, Soslow RA, Iasonos A, Linkov I, Hedvat C, Bonham L, Singer J, Barakat RR, Aghajanian C, Dupont J. Diefenbach CS, et al. Among authors: aghajanian c. Cancer. 2006 Oct 1;107(7):1511-9. doi: 10.1002/cncr.22184. Cancer. 2006. PMID: 16944535 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

302 results

Search Page